Lumiracoxib (Novartis).
Lumiracoxib, an inhibitor of cyclooxygenase 2 (COX-2), is under development by Novartis for the potential treatment of osteoarthritis, rheumatoid arthritis and pain. By late December 2000, phase III trials had been initiated and were ongoing in December 2001.
Ding
Changhai
C
Menzies Centre for Population Health Research, University of Tasmania, 17 Liverpool Street, Hobart 7000, Tasmania, Australia. chding@utas.edu.au
Jones
Graeme
G